Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Feb 2023
As more states repeal or restrict abortion laws, the number of patients, the number of workers needed, and the cost of heart disease will increase. How should hospitals and policy makers prepare?
Read Full NewsNew findings from the EMBARK study highlight Elevidys' significant long-term benefits in slowing Duchenne muscular dystrophy progression in young patients.
A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.
FDA Approves First Dual-Agent Eye Drop for Near Vision Loss
1.
Through the activation of bitter taste receptors, lidocaine has the potential to kill some cancer cells.
2.
Nearly 4 million lung cancer deaths averted and 76 million years of life gained due to tobacco control in US
3.
Access to GLP-1 medications associated with a lower risk of colorectal cancer in people with type 2 diabetes: JAMA.
4.
Team finds broken 'brake' on cancer mutation machine.
5.
Mapping lifelong chronic health risks for childhood cancer survivors
1.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
2.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
3.
Giant Sebaceous Cyst of the Scalp Mimicking a Soft Tissue Tumor: A Case Study
4.
Exosomes in Cancer: A Novel Frontier for Therapy and Biomarker Discovery
5.
Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Efficient Management of First line ALK-rearranged NSCLC - Part III
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge